JENBURKT PHARMACEUTICALS LTD. (JENBURPH) Fair Value & Analysis

Healthcare · IN · Market cap ₹4.9B

A solid business, currently priced close to our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The model range is unusually wide (₹585.71 to ₹1,694). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• The price sits close to our fair value, market and models broadly agree here, little valuation tension.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹359.90 – ₹1,375 · fair‑value band ₹585.71 – ₹1,694 · the ₹1,034 price screens above the ₹1,011 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

JENBURKT PHARMACEUTICALS LTD. (JENBURPH) currently trades at ₹1,034, while our model-based Fair Value estimate is ₹1,011, implying the stock looks roughly 2.3% fairly valued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, JENBURKT PHARMACEUTICALS LTD. generated revenue of ₹1.7B at a net margin of 20.6%. Revenue grew 8.7% year over year. It earns a return on equity of 18.8%. Net debt stands at ₹7.8M. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹585.71 (bear case) to ₹1,694 (bull case); at ₹1,034, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -2%, JENBURPH screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹1,554) versus Dividend Discount (₹262.74). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India.

Full company description

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. The company provides its products through stockists, doctors, pharmacies, chemists, large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. It exports its products to approximately 13 countries worldwide. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

JENBURKT PHARMACEUTICALS LTD. reported revenue of ₹1.7B in FY2026 versus ₹1.2B in FY2022, a compound +8.1%/yr. Reported net income was ₹347M in FY2026, compounding +11.7%/yr from FY2022.

Watch JENBURPH: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 639 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.